Kanika Sehgal, MBBS: The State of C Difficile Care

Video

There are several potential treatments on the horizon for C difficile infections.

The state of care for C difficile infections is improving rapidly by the day.

Fecal microbiota transplantation (FMT), live microbiome therapeutics (LMT), and new antibiotics have drastically led to improving care.

And a lot of the measures put in place during the COVID-19 pandemic has led to a drop in hospital-acquired infections.

With the state of care improving, new research suggests C difficile cases are not related to an increased risk of emotional distress for patients.

In an interview with HCPLive®, Kanika Sehgal, MBBS, Research Fellow at Mayo Clinic Rochester, explained the current state of C difficile care.

Sehgal recently presented data at 2022 Digestive Disease Week Annual Meeting in San Diego, on the psychological distress in patients at the time of symptom development for CDI.

In the study, the investigators examined adult patients with an index episode of CDI, no history of irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD).

All 8 patients developed abdominal pain that was present for at least 1 day per week and was related to change in bowel movement consistency and frequency.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.